GlassScriptPhysician profile
Joanna Ferrell
NPI 1003323148
$6,647.82
in general payments reported to CMS, 2019-2025
32 companies · $2,346 in 2025
The $2,346 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $166 · 2023: $1,507 · 2024: $2,353 · 2025: $2,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,928 · Education: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,927.53 |
| Education | $278.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,470.70 | 2022-2025 | Ilumya, Absorica Ld, Winlevi |
| Regeneron Healthcare Solutions, INC. | $790.64 | 2022-2025 | Dupixent, Libtayo |
| Abbvie INC. | $561.42 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $505.40 | 2021-2025 | |
| Ucb, INC. | $425.21 | 2023-2025 | Bimzelx |
| Genzyme Corporation | $358.55 | 2023-2025 | |
| Janssen Biotech, INC. | $347.35 | 2023-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $290.26 | 2024-2025 | Otezla, Otezla |
| Abbott Laboratories | $289.69 | 2023 | Proclaim, Eterna |
| Lilly USA, LLC | $242.32 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $206.81 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $192.74 | 2023-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $167.35 | 2023-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $162.19 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $138.25 | 2023-2025 | Cabtreo, Duobrii, Arazlo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $78.19 | 2021 | |
| Arcutis Biotherapeutics, INC. | $77.91 | 2024-2025 | Zoryve |
| Novo Nordisk INC | $62.37 | 2021 | |
| Verrica Pharmaceuticals INC. | $35.66 | 2023-2024 | Ycanth |
| Dermavant Sciences, INC. | $26.55 | 2023 | Vtama |
| Genentech USA, INC. | $25.84 | 2021 | |
| Esperion Therapeutics, INC. | $22.35 | 2021 | |
| Biogen, INC. | $21.71 | 2021 | |
| Botanix Sb INC | $21.23 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $19.88 | 2025 | Nemluvio |
| Daiichi Sankyo INC. | $18.83 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.27 | 2021 | |
| Pfizer INC. | $14.96 | 2023 | |
| Mindera Corp | $14.63 | 2025 | |
| Organon LLC | $14.27 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $13.90 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.39 | 2024 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Ferrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.